FNY Investment Advisers’s Revance Therapeutics, Inc. RVNC Stock Holding History

FNY Investment Advisers’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-477,823	Closed	-$1.45M	–	1057
2024 Q4	$1.45M	Buy	477,823 +294,323	+160%	+$1.28M	0.75%	35
2024 Q3	$952K	Buy	+183,500	New	+$912K	0.46%	64
2022 Q1	–	Sell	-15	Closed	–	–	951
2021 Q4	$0	Buy	+15	New	+$250	﹤0.01%	850
2020 Q1	–	Sell	-1,000	Closed	-$16K	–	878
2019 Q4	$16K	Buy	+1,000	New	+$15.5K	0.01%	599
2019 Q3	–	Sell	-2,901	Closed	-$37K	–	1213
2019 Q2	$37K	Buy	+2,901	New	+$36.6K	0.01%	404

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

FNY Investment Advisers's RVNC Position: Q1 2025 in Review

FNY Investment Advisers sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 477,823 shares — an estimated $1.45M sold.

FNY Investment Advisers first reported a position in RVNC in Q2 2019 and held it in 5 quarters. The position peaked at $1.45M in Q4 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

FNY Investment Advisers reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
FNY Investment Advisers sold 477,823 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $1.45M.
FNY Investment Advisers first reported a position in Revance Therapeutics, Inc. in Q2 2019 and held it in 5 quarters.
FNY Investment Advisers's Revance Therapeutics, Inc. position peaked at $1.45M in Q4 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on FNY Investment Advisers's 13F filing for Q1 2025, filed 17 Apr 2025.